Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$6.11 USD
+0.41 (7.19%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $6.08 -0.03 (-0.49%) 6:00 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Emergent Biosolutions Inc. [EBS]
Reports for Purchase
Showing records 221 - 237 ( 237 total )
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Reports Q1 EPS, Misses Top-Line, Lowers Q2 Guidance, but Retains FY:11 Guidance, Updates Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 27
Provider: WEDBUSH SECURITIES INC.
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of March 6
Provider: WEDBUSH SECURITIES INC.
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Updates Guidance, Increasing Price Target to $32 from $27.
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Q3 earnings; Raising our BioThrax Sales Expectations and TRBN Acquisition Lead to Increased Price Target to $27 from $22
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Q2:10 Earnings - EBS Reiterates 2010 Revenue Guidance
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Receives Contract Valued Up to $106.9 Million for BioThrax Manufacturing Scale-up
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Emergent Biosolutions Inc.
Industry: Medical - Biomedical and Genetics
Q1:10 Earnings - Q1 Revenue Below Expectations, But We Remain Confident in the 2010 Revenue Guidance
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G